ストックスクリーナーアプリを入手
6.03
0.33%
0.02
アフターアワーズ：
6.02
-0.01
-0.17%
前日終値:
$6.01
開ける：
$6.02
24時間の取引高:
125.55K
Relative Volume:
0.42
時価総額：
$311.68M
収益：
-
当期純損益:
$-19.90M
株価収益率:
-11.38
EPS:
-0.53
ネットキャッシュフロー:
$-19.80M
1週間 パフォーマンス:
+29.12%
1か月 パフォーマンス:
+40.23%
6か月 パフォーマンス:
-4.13%
1年 パフォーマンス:
+71.79%
1日の値動き範囲:
$6.00
$6.14
1週間の範囲:
$4.39
$6.40
52週間の値動き範囲:
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
名前
Diamedica Therapeutics Inc
セクター
電話
(763) 496-5454
住所
301 CARLSON PARKWAY, MINNEAPOLIS, MN
DMAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.03 | 309.45M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-06-22 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 開始されました | Oppenheimer | Outperform |
| 2021-02-17 | 開始されました | ROTH Capital | Buy |
| 2020-10-30 | 開始されました | Guggenheim | Buy |
| 2020-07-08 | 開始されました | Maxim Group | Buy |
| 2019-04-30 | 開始されました | Dougherty & Company | Buy |
| 2019-03-05 | 開始されました | Lake Street | Buy |
すべてを表示
Diamedica Therapeutics Inc (DMAC) 最新ニュース
Can machine learning forecast DiaMedica Therapeutics Inc. recovery2025 Performance Recap & Real-Time Volume Analysis - Newser
Will DiaMedica Therapeutics Inc. see short term momentumWeekly Volume Report & Free Community Consensus Stock Picks - Newser
Statistical indicators supporting DiaMedica Therapeutics Inc.’s strengthIPO Watch & Target Return Focused Stock Picks - Newser
Technical analysis overview for DiaMedica Therapeutics Inc. stockTrade Ideas & Daily Price Action Insights - Newser
Custom strategy builders for tracking DiaMedica Therapeutics Inc.Product Launch & Advanced Technical Signal Analysis - Newser
Identifying reversal signals in DiaMedica Therapeutics Inc.2025 Investor Takeaways & Verified Momentum Stock Alerts - Newser
DiaMedica Therapeutics Inc (DMAC) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2025 Earnings Call Transcript - Insider Monkey
DiaMedica advances DM199 programs with $60M cash runway and expanded clinical trials - MSN
DiaMedica Therapeutics Advances with Positive Trials and Funding - TipRanks
Intrinsic Value of DiaMedica Therapeutics Inc. Stock: Is It Undervalued or OvervaluedShare Buyback & Real-Time Buy Signal Notifications - Newser
DiaMedica Therapeutics reports Q2 EPS (18c), consensus (19c) - MSN
DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia (NASDAQ:DMAC) - Seeking Alpha
Diamedica Therapeutics shares rise 14.94% intraday after Celcuity's positive Phase 3 trial results. - AInvest
DiaMedica Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Diamedica Therapeutics shares rise 1.92% intraday after Q2 2025 earnings call. - AInvest
Earnings call transcript: DiaMedica Therapeutics Q2 2025 shows promising trials By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Therapeutics Q2 2025 shows promising trials - Investing.com India
What to expect from DiaMedica Therapeutics Inc. in the next 30 daysWeekly Market Summary & Expert Approved Momentum Ideas - Newser
Pattern recognition hints at DiaMedica Therapeutics Inc. upside2025 Trade Ideas & Fast Gain Stock Tips - Newser
Technical signs of recovery in DiaMedica Therapeutics Inc.Weekly Investment Report & Free Reliable Trade Execution Plans - Newser
DiaMedica Posts Narrower Loss in Q2 - AOL.com
What indicators show strength in DiaMedica Therapeutics Inc. [Short Setup]Weekly Top Gainers Trade List - Newser
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - BioSpace
Full technical analysis of DiaMedica Therapeutics Inc. stockAI Intraday Market Movement Prediction Tool - Newser
DiaMedica Therapeutics Enters Sales Agreement with TD Securities - TipRanks
Is this a good reentry point in DiaMedica Therapeutics Inc.Fast Entry Strategy with Price Prediction - Newser
DiaMedica Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can DiaMedica Therapeutics Inc. sustain its profitabilityReal-Time Trade Breakout Scanner - thegnnews.com
Screener Results Flag DiaMedica Therapeutics Inc. as OversoldROI Driven Equity Selection With Safety Emphasized - 선데이타임즈
What data driven models say about DiaMedica Therapeutics Inc.’s futureRapid Trade Forecast Based on Indicators - Newser
Momentum divergence signals in DiaMedica Therapeutics Inc. chartAutomated AI Forecast with Trading Alerts - Newser
Fair Value Estimate for DiaMedica Therapeutics: $5.11; Share Price Matches Fair Value; Analyst Price Target Exceeds Fair Value. - AInvest
Volume spikes in DiaMedica Therapeutics Inc. stock – what they meanShort-Term AI-Based Stock Price Forecast - Newser
What’s the recovery path for long term holders of DiaMedica Therapeutics Inc. - Newser
What makes DiaMedica Therapeutics Inc. stock price move sharplyFree AI Based High Gain Watchlist Scanner - Newser
Press Release: DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 - 富途牛牛
Can momentum traders help lift DiaMedica Therapeutics Inc.Free Low Risk Buy Zone Opportunity Watch - Newser
DiaMedica Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
What indicators show strength in DiaMedica Therapeutics Inc.Conservative Equity Setup with Signal Analysis - Newser
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
DiaMedica Appoints New Chief Medical Officer - The Globe and Mail
Diamedica Therapeutics Inc (DMAC) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):